Marijuana-Based Epilepsy Drug, Epidiolex priced at $32,500 for a Year


GW Pharmaceuticals, in its latest quarterly earning call, conducted on August 7 2018, finally announced the price of its cannabis-based epilepsy drug Epidiolex. The drug would be priced at $32,500 per patient annually. Epidiolex was approved this year by the U.S. FDA for the treatment of two rare forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome.

The company informed that the pricing approach has been discussed with the patient community which it will serve. According to a call transcript, sourced from Seeking Alpha, Gangolli said the payers are supportive of the rationale that “Epidiolex should be priced in line with the branded anti-seizure therapies prescribed for these intractable patients.”

“The analysis of the direct cost burden associated with LGS and Dravet syndrome in the U.S. showed a substantial cost burden for both conditions, and further highlights the need for this new therapeutic option,” Gangolli said.

Justin Gover, GW’s Chief Executive Officer further said that they expect to make Epidiolex available to U.S. patients this fall, following rescheduling, which is expected to occur within 90 days of FDA approval. The FDA has communicated its recommendation to DEA, and the company understands that the rescheduling process is proceeding in a normal fashion and that it will be completed within the expected 90-day timeframe. GW Pharmaceuticals has been building commercial inventory in recent months and are in a position to ship product into the U.S. supply chain, once rescheduling is complete.


About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Epilepsy indication, visit


News Source:

Image Source: